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ABSTRACT: Microbial bioﬁlms possess intrinsic resistance
against conventional antibiotics and cleaning procedures; thus,
a better understanding of their complex biological structures is
crucial in both medical and industrial applications. Existing
laboratory methodologies have focused on macroscopic and
mostly indirect characterization of mechanical and micro-
biological properties of bioﬁlms adhered on a given substrate.
However, the kinetics underlying the bioﬁlm formation is not
well understood, while such information is critical to
understanding how drugs and chemicals inﬂuence the bioﬁlm
formation. Herein, we report the use of localized surface
plasmon resonance (LSPR) for real-time, label-free monitor-
ing of E. coli bioﬁlm assembly on a nanoplasmonic substrate
consisting of gold mushroom-like structures. Our LSPR sensor
is able to capture the signatures of bioﬁlm formation in real-time by measuring the wavelength shift in the LSPR resonance peak
with high temporal resolution. We employ this sensor feature to elucidate how bioﬁlm formation is aﬀected by diﬀerent drugs,
including conventional antibiotics (kanamycin and ampicillin) as well as rifapentine, a molecule preventing cell adhesion yet
barely aﬀecting bacterial viability and vitality. Due to its ﬂexibility and simplicity, our LSPR based platform can be used on a
wide variety of clinically relevant bacteria, thus representing a valuable tool in bioﬁlm characterization and drug screening.
KEYWORDS: bioﬁlms, real-time monitoring, LSPR, antibiotics, drug screening, E. coli
Bacteria exhibit two types of growth regimes: planktonic,where cells are freely moving in a bulk solution, and
sessile aggregates known as bioﬁlms.1,2 In the latter form, the
microorganisms are closely packed on a solid surface within
self-produced matrix of extracellular polymeric substances
(EPS). This structure provides many structural and functional
beneﬁts such as improved resource capture, adhesion to
surfaces, digestive capacity, protection against external agents,
and inhibition of bacterial dehydration. Furthermore, the EPS
scaﬀold facilitates intercellular interactions and horizontal gene
transfer.3 Another key feature of bacterial bioﬁlms concerns the
development of their peculiar resistance against antimicrobial
agents.4 Some of their possible protection strategies involve
poor antibiotic penetration, formation of gradients of nutrients
or cell products, and phenotypic diﬀerentiation induced by the
EPS matrix.5,6 In addition, the lack of nutrients and the high
concentrations of bacterial metabolites in bioﬁlms result in
areas where cells are in a stationary phase (a slow or
nongrowth phase of bacterial growth cycle), which become
mostly immune to conventional antibiotic drugs since they
target speciﬁcally to the metabolically active microorganisms.7
Because of their unique properties, bacterial bioﬁlms have
been actively studied across diverse ﬁelds, ranging from
industrial processes to medicine. For example, bioﬁlms have
been used in bioremediation, waste treatment, and production
of ﬁne chemicals and biofuels.8 On the other hand, bioﬁlms are
associated with serious health issues stemming from persistent
infections due to the contamination of medical devices (e.g.,
intravenous and urinary catheters), artiﬁcial implants,9 and
pollution of drinking water.10 Similar concerns have been
recently raised by the world health organization (WHO)
through their ﬁrst global antimicrobial resistance surveillance
system (GLASS) report.11 In this context, bacterial detection,
antibiotic susceptibility, and the rise of antibiotic resistant
microorganisms are pressing issues requiring novel and
sensitive detection strategies which can also be adopted to
screen new drugs. For instance, Jo et al.12 recently developed a
capacitive aptamer-based biosensor to monitor the bacterial
growth and antibiotic susceptibility in real-time. In another
study, Brosel-Oliu et al.13 detected pathogenic E. coli using
impedance spectroscopy. However, both approaches focused
on the detection of single planktonic bacteria instead of
microbial bioﬁlm formation. In contrast, bioﬁlm assembly
requires the direct adhesion of the bacterial cells onto the
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substrate because the use of a capturing element (e.g.,
aptamers or antibodies) prevents the bioﬁlm detection under
its native condition. Moreover, since bacteria in bioﬁlms are
extremely resistant to conventional drugs, there is a
tremendous interest in discovering new bioﬁlm speciﬁc
antibiotics that can penetrate the polymeric matrix, thus
reaching bacterial cells, and/or aﬀecting the EPS structure to
destabilize the bioﬁlm so that standard antibiotics can
subsequently attack the microorganisms.
Motivations described above underpin the research on
developing reliable characterization tools to provide the real-
time monitoring of bioﬁlm formation under diﬀerent drugs and
chemicals. This activity is promising since detailed information
on the bioﬁlm growth kinetics is extremely valuable in
discovering novel treatments and drugs to combat bioﬁlm
related infections (e.g., types and concentrations of antibiotics
to use). A comparative overview of the latest technologies
reported for the characterization of bacterial bioﬁlm is
summarized in Table 1 while more details about these
methodologies can be found in the Supporting Information.
Recently, nanomaterial based label-free photonic biosensors
have revealed unprecedented information on DNA and protein
molecular interactions, ﬁnding wide applications in medical
diagnostics, food safety, and environmental monitoring.33,34
However, few attempts have been made to apply label-free
photonic biosensors to cellular assays, as it is challenging to
develop nanostructured substrates with large surface areas that
promote both sensing and long-term cell survival. Localized
surface plasmon resonance (LSPR) is the coherent oscillation
of the surface electrons of metal nanostructures due to
interactions between the incident light and the conduction
band electrons of the metal.35,36 This technology has been
utilized to perform highly sensitive label-free detection of
biomolecular interactions in real time, an essential feature for
the early detection of diseases and point-of-care (POC) clinical
evaluations. However, most recent uses of plasmonic materials
Figure 1. LSPR biochip and microscopic characterization of the plasmonic nanostructures. (a) Snapshot of the device. (b) Schematic of the Au
NM LSPR substrate. In order to monitor the bacterial bioﬁlm formation, the nanostructured glass substrate bonds with a PDMS slab containing
multiwell structures, where each well can accommodate up to 150 μL of cell suspensions. The AFM scan of the Au NM substrate with (c) a 2 μm ×
2 μm scan area; (d) magniﬁcation of a 500 nm × 500 nm area. This set of measurements shows the uniformity of the Au NM, with an average
roughness of 2.0 ± 0.1 nm. SEM images of Au NMs acquired at 100 000× magniﬁcation: (e) top; and (f) tilted (40°) images.
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on bioﬁlms exploited the local temperature increase induced by
the LSPR eﬀect to prevent bioﬁlm formation.37−39
We have recently demonstrated a biocompatible nano-
plasmonic substrate by developing a gold-based nanoplasmonic
material for long-term monitoring of eukaryotic cell prolifer-
ation.40 In this work, by using a similar nanofabrication
protocol, we report the use of LSPR for characterizing bioﬁlm
formation on a highly sensitive, large-scale, and biocompatible
nanoplasmonic substrate containing high density gold nano-
mushroom structures. Our LSPR substrates consist of gold
mushroom-like structures, with stems of silicon dioxide and
caps of gold on the order of 30 nm in diameter, to achieve the
LSPR eﬀect. Speciﬁcally, the model organism Escherichia coli (
E. coli) is used for all studies. The localized surface plasmons
on the nanomushroom caps are exploited to monitor bioﬁlm
formation without any labeling procedure. In addition, we have
developed an automated high resolution system allowing the
real-time monitoring of bioﬁlm formation by continuously
illuminating the LSPR biochip in a Faraday cage and recording
the resonance peak shift every minute for 24 h. Since LSPR
eﬀect is very sensitive to changes of a few tens of nanometers
from the sensor surface, our methodology enables precise
monitoring of the activities in the bottom layer of the adhering
bioﬁlm, which is diﬃcult to achieve by using conventional
techniques. This information is of paramount importance for
ﬁghting persistent infections in bioﬁlms, since the microbial
cells in direct contact with the substrate are mostly protected
from the external environment, thus guarded against antibiotic
treatment. As a proof of concept study, we further apply our
LSPR chips to investigate how three diﬀerent types of
antibiotics aﬀect the E. coli growth as well as the bioﬁlm
formation. We demonstrate that our biochip serves as a
powerful characterization tool for investigating real-time
bioﬁlm formation, screening of new drugs, and evaluating
alternative cleaning procedures.
■ EXPERIMENTAL SECTION
Bacterial Growth. Precultures of wild type strain MC4100 (K12
derivative) are grown overnight in a 20 mL lysogeny broth (LB) (rich
media), shaken at 200 rpm at 37 °C. The cultures are back-diluted to
1:200 in a fresh LB media after overnight culture. This roughly
corresponds to 2 × 107 CFU mL−1, as estimated from counting single
colonies from serial dilutions on LB-agarose ﬁlled Petri dishes. The
cultures are gently vortexed before a volume of 125 μL of the sample
is directly aliquoted into the microwells of the LSPR biochip.
LSPR Biochip Fabrication. The gold (Au) nanomushroom
(NM) based LSPR chip is fabricated by a 3-step process. First, we
deposit 5 nm Au ﬁlm onto a SiO2 substrate at 0.1−0.2 Å s−1 using an
e-beam evaporator (KE604TT1-TKF1, Kawasaki Science) in a class
1000 clean room. Prior to deposition, SiO2 substrates were cleaned
with acetone and isopropanol. Next we anneal the 5 nm gold ﬁlm at
560 °C for 3 h to generate a distribution of Au nanoislands on the
SiO2 substrate. Finally, we selectively etch the Au nanoislands on SiO2
to generate mushroom like structures using reactive ions of SF6. The
reactive ion etching (RIE) is performed by inductively coupled plasma
(ICP) chemical vapor deposition equipment (Plasmalab 100, Oxford
Instruments). SF6 gas is introduced inside the RIE-ICP chamber,
maintained at an inside pressure of 10 mTorr and a ﬂow rate of 45
sccm (standard cubic centimeters per minute). The RF power coil
and the RF bias coils are ﬁxed to 150 and 10 W, respectively, and the
temperature inside the plasma chamber is maintained at 5 °C. The
total duration of RIE is 5 min. More details on the fabrication
techniques can be found in our recent work.41
To fabricate PDMS wells, we ﬁrst make slabs of PDMS by pouring
10:1 polydimethylsiloxane (PDMS) (Dow Corning, Japan) in a Petri
dish and then cure the prepolymer for 3.5 h at 60 °C after degassing
to remove air bubbles. We then punch holes of 8 mm in diameter by
using disposable biopsy punchers (Kai Medical, Japan) to create
PDMS wells. Both PDMS and the NM substrate are exposed to
oxygen plasma (Harrick Plasma, USA) at 30 W for 1 min. After
plasma treatment, PDMS well and NM based LSPR substrate are
immediately brought in close contact to ensure strong bonding
(Figure 1a). This treatment ensures proper conﬁnement of the sample
solution without any leakage. Thereafter the developed LSPR
biochips are used for bacterial bioﬁlm sensing.
Morphological Characterization of the LSPR Substrate.
AFM imaging is performed in tapping mode using a Dimension Icon3
(Bruker, Japan) microscope equipped with an aluminum back-coated,
antimony-doped Si cantilever from Bruker (TESPA-V2), with typical
values of a nominal tip radius ∼8 nm, spring constant k ≈ 42 N m−1,
and resonance frequency f 0 ≈ 320 kHz. Areas of 4 μm2 and 0.25 μm2
have been scanned under a scanning speed of 1 Hz, with a resolution
of 512 pixels per line, and a relatively high amplitude set-point ratio
(Asp/Afree ≈ 0.85; Afree ≈ 23 nm; Asp ≈ 17 nm). All the measurements
have been repeated three times and the experimental results have
been processed using NanoScope Analysis 1.8 software (Bruker,
USA).
The scanning electron microscopy (SEM) is carried out by using a
high performance scanning electron microscope (FEI Quanta 250
FEG, Thermo Fisher Scientiﬁc). Images are acquired at 20 kV, with a
magniﬁcation of 100 000× inside a vacuum chamber maintained at a
pressure of 10−4 Pa. To avoid charging of SiO2 surfaces during
imaging, the NM substrates are coated with Pt/Pd at a few angstroms
thickness. The top view of the NM substrate is captured with the
electron gun placed normal to the substrate. In contrast, the side view
of the NM substrate is captured by tilting the electron gun at 40°. The
SEM images are processed with ImageJ software to analyze detailed
morphological features such as the size and gaps between the NM
structures.
Sensing Procedure. The instrument involving LSPR consists of
two ﬁber optics patch cords, one connected with a halogen light
source (LS-1-LL) and the other connected to the spectroscope
(USB4000-UV-vis-ES). All discrete components (spectrometer, light
source, and patch chords) are purchased from Ocean Optics (Japan).
The LSPR signals are acquired in T-LSPR (Transmission) mode.
Before taking any signal from the spectroscope, the system is
calibrated for dark and light spectrum modes. The LSPR signal is then
recorded in absorption mode by observing the wavelength depend-
ence of the light absorbed by Au NM via the Spectrasuite software
(cross-platform spectroscopy operating software from Ocean Optics).
For noncontinuous experiments, the biochip containing the bacteria
grows in a Taitec BR-23PF incubator (Japan) under 37 °C, but the
biochip is removed from the incubator periodically for the absorption
spectrum acquisition under room temperature. The real-time
measurements are performed in a Faraday cage under continuous
illumination for 24 h. The real-time measurements are acquired by
processing the spectrometer data through a homemade graphics user
interface on a Matlab platform. The data are then analyzed using
OriginPro 2017 (OriginLab, USA).
Crystal Violet Staining. Crystal violet (CV) assay is a well
established methodology to evaluate bioﬁlm formation under various
growth conditions (e.g., drug screening, strain comparison).42,43 For
this reason, the CV assay is used to validate the measurements from
our LSPR biochip system. The detailed procedure is reported in the
Supporting Information.
Viability Staining. LIVE/DEAD BacLight Bacterial Viability Kit
(L13152) from Invitrogen has been used to evaluate cell viability on
Au NM LSPR substrate and investigate the eﬀect of the continuous
white light illumination on E. coli cells. The detailed protocol is
reported in the Supporting Information.
■ RESULTS AND DISCUSSION
Characterization of the Nanoplasmonic Chip. An
integrated LSPR biochip (Au NM LSPR substrate bonded
with PDMS wells) is shown in Figure 1a. The nanostructured
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SiO2 substrate is optically translucent and pink in color due to
the presence of plasmonic Au nanostructures. The Au
nanostructures have a characteristic pillar shape, with the
schematic shown in Figure 1b. The morphological features of
the substrate such as the size of the Au NM, gap size between
NMs, and their surface density is characterized by using
tapping mode atomic force microscopy (AFM) and scanning
electron microscopy (SEM), which provide detailed nano-
metric features of the LSPR substrate (Figure 1). Based on the
AFM images (Figure 1c and d), the Au NMs are quasi-
uniformly distributed on the SiO2 surface (∼106−108 NM
cm−2) with a root-mean-square roughness of 2.0 ± 0.1 nm.
Based on the high contrast images between Au NMs and the
glass substrate obtained by SEM (Figure 1e and f), the average
diameter of NMs is 29 ± 0.3 nm (standard error of mean, SE)
and 29 ± 14 nm (standard deviation, SD). The average spacing
among the Au NMs is 9 ± 1 nm (SE) and 9 ± 6 nm (SD).
For LSPR sensing applications, the average refractive index
(RI) sensitivity of our NM LSPR substrate is estimated as 98.6
nm RIU−1 (see more details in the Supporting Information).
The sensitivity of the Au NM can be tuned by changing the
size and gaps of the NM structures (discussed in our previous
work40). Note that the size and morphology of Au
nanostructures are also crucial for the biocompatibility of the
LSPR substrate when it is in direct contact with live entities
such as bacteria, virus, and eukaryotic cells.40 In later sections
we will discuss the eﬀects of the continuous exposure of LSPR
illumination on the bacterial growth.
LSPR Monitoring of Bacteria Bioﬁlm Formation. The
local sensitivity and the reliability of our Au NM LSPR
substrate have been exploited to develop a new character-
ization tool to monitor the E. coli growth and bioﬁlm
formation. E. coli strains can be both nonpathogenic and
pathogenic. The nonpathogenic ones are harmless and easy to
manipulate, and hence will be used as our model micro-
organism to optimize the sensing procedure. However, the
pathogenic E. coli strains are important since they are
responsible for a wide range of diseases, e.g., urogenital
infections where bacterial cells form bioﬁlms.44 Nevertheless,
our studies can be easily expanded to other bacterial systems.
Below we will illustrate both noncontinuous and real-time
LSPR monitoring of bacterial bioﬁlm formation by using a
model nonpathogenic E. coli system.
Noncontinuous Monitoring. To study the bioﬁlm
formation, an inoculum of E. coli (125 μL, 2 × 107 CFU
mL−1) is loaded into our LSPR biochip and the bacterial
growth is then monitored for about 30 h. For the non-
continuous monitoring, the LSPR biochip is removed from an
incubator at 37 °C only periodically when it is required to
collect the absorbance spectrum (∼10 s).
Figure 2. Noncontinuous LSPR monitoring the bacterial adhesion and bioﬁlm formation in the LB culture media. While the bacterial growth is
performed at 37 °C in an incubator, the absorbance data are obtained at room temperature and take less than 10 s for each measurement. (a)
Normalized absorbance spectra for the LSPR biochip incubated with an E. coli sample in the LB medium, with zoomed-in details in the wavelength
of 546−564 nm region. The peak position shifts to shorter wavelengths during bioﬁlm assembly. The black arrow highlights the progressive blue
shift due to microbial bioﬁlm assembly. (b) Absorbance peak position as a function of time. The control experiment performed using only LB
culture media produces a negligible shift in the signal (blue circles) when compared with the sample containing E. coli (red squares). Each data
point corresponds to at least 3 repetitive experiments (n ≥ 3), with the error bars denoting the standard error of mean (SE). (c) Bacterial growth
monitored at 0, 1, 6, 12, 18, and 24 h, captured by bright-ﬁeld microscopy (Eclipse Ti−U, Nikon Instruments Inc.). The series of images illustrate
the progress of the bioﬁlm formation in a LSPR biochip.
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As shown in Figure 2a and b, bacterial growth and adhesion
on the Au NM substrate produce a signiﬁcant blue shift in the
absorbance peak of the Au NM, which can be attributed to the
charge changes in the overall system upon bioﬁlm formation.
As the bacterial ﬁlm assembly progresses, the charge on the
NM substrate increases with the increasing amount of bacteria,
protein, and polysaccharide secretion,45,46 which eventually
leads to the formation of bioﬁlm. Recall that bioﬁlm is a slimy
matrix composed of mostly proteins and polysaccharides, the
latter being negatively charged at physiological pH.47 The
increase in the surface charge of Au NM during the bioﬁlm
formation further leads to an enhanced frequency of plasmonic
resonances because the frequency of plasmons is directly
proportional to the amount of the charge on the plasmonic
material. The increase in the frequency also causes a decrease
in the LSPR wavelength, suggesting that the observed blue
shifts in the wavelength peak correspond to the bacterial
bioﬁlm formation. Red square symbols in Figure 2b illustrate
that the LSPR signal saturates around 8 h, correlated with the
completion of the bioﬁlm assembly. For comparison, by
incubating the LSPR substrate with the culture medium (LB)
for 30 h, only negligible wavelength shift is observed (blue
circles in Figure 2b).
The LSPR resonance wavelength versus time data (Figure
2b, red squares) is ﬁtted by using a modiﬁed logistic-type
function:
λΔ = + −
+ − *
b
a b
1 e
,
k t t( ) (1)
where Δλ is the wavelength shift in nanometer, a and b are the
initial and the ﬁnal wavelength values, respectively, k is a rate
parameter, and t* corresponds to the time upon which the
growth and bioﬁlm formation rates are maximized and half of
the wavelength shift (a−b) is achieved. By ﬁxing the initial
value (a = 0), the best ﬁt of the experimental responses due to
the bacterial growth yields b=−15.6 ± 0.5 nm, k = 0.93 ±
0.18 h−1, and t*=5.8 ± 0.3 h.
The bioﬁlm formation is also conﬁrmed by bright-ﬁeld
microscopy (Figure 2c), which reveals that bacterial growth is
barely aﬀected by the nature of the plasmonic substrate nor the
LSPR sensing setup. This observation is promising since LSPR
substrate has been reported to induce local temperature jump
and cause cell death.48 Our results demonstrate that our Au
NM LSPR substrate is biocompatible and enables the bacteria
to form bioﬁlm with sustained viability for more than 30 h.
This simple LSPR platform also allows us to easily evaluate
detailed kinetics underlying the bioﬁlm formation and can be
used to compare diﬀerent types of microorganisms or testing
the eﬀect of drugs on the bacterial growth.
However, to obtain each measurement point at a speciﬁc
time (shown in Figure 2b), the LSPR biochip has to be
removed from the 37 °C incubator periodically to capture
LSPR signals; hence, some inevitable changes in the LSPR
biochip position through the manual alignment and the
environmental light have led to some random ﬂuctuations in
the resonance peak wavelength (the error bars in Figure 2b
represent the standard error of mean, n ≥ 3). To reduce the
contribution of these random ﬂuctuations, we present the real-
time continuous monitoring procedure below.
Real-Time Continuous Monitoring. To enhance the
sampling frequency and overcome the noise issues from the
noncontinuous monitoring, we have developed an automatized
system to provide the real-time monitoring of the local
refractive index changes (hence the LSPR signals) as soon as
the E. coli is deposited in the PDMS well of the LSPR biochip.
To prevent sample evaporation, the LSPR biochip is conﬁned
in a transparent chamber with a water reservoir. Both bacterial
growth and the absorbance spectrum are recorded in a Faraday
cage to eliminate the noise caused by the environmental light.
Once the chip is orthogonally aligned between the two optical
ﬁbers, we use a custom-made software to record the
absorbance spectrum every minute for a duration of 24 h,
thus achieving a much better resolution than those from the
noncontinuous measurements. Sensor signals obtained during
the ﬁrst 24 h when an LSPR chip is incubated with an E. coli
sample in the LB medium, are shown in the Supporting
Information, consistent with the noncontinuous measure-
ments.
The stability of the LSPR reading and any nonspeciﬁc
response resulting from the continuous illumination of the
LSPR biochip is ﬁrst evaluated by recording the transmitted
light of a bare Au NM LSPR sensor, in contact with air, for
24 h. The LSPR signals appear to be quite stable for the whole
duration of the experiment (purple triangles in Figure 3a).
Thereafter, the same real-time monitoring LSPR procedure is
used to compare responses from diﬀerent samples: plain
Figure 3. Real-time monitoring of bacterial adhesion and bioﬁlm
formation. (a) Resonance wavelength as a function of time for the
control (LB), E. coli, and E. coli growing in the presence of various
antibiotics and antibiotic mixture (kanamycin: 100 μg mL−1,
ampicillin: 100 μg mL−1, rifapentine: 1 μg mL−1). The stability of
the sensing platform is evaluated by measuring the resonance peak of
the LSPR biochip for 24 h when exposed to air (purple triangles).
Peak positions are estimated by ﬁtting the spectra in the 520−600 nm
region using a spline function. (b) Magniﬁcation of the sensor
responses for the ﬁrst 5 h where the experimental data are shown with
the best curve ﬁts.
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culture medium (LB), E. coli in LB medium, and E. coli treated
with diﬀerent antibiotics (kanamycin at 100 μg mL−1,
ampicillin at 100 μg mL−1, rifapentine at 1 μg mL−1, and a
mixture of the three drugs (kanamycin at 100 μg mL−1;
ampicillin at 100 μg mL−1; rifapentine at 1 μg mL−1)). These
antimicrobial agents attack diﬀerent aspects of bacteria
metabolisms. Kanamycin and ampicillin are standard anti-
biotics: kanamycin interacts with the ribosomes aﬀecting
protein synthesis while ampicillin inhibits the transpeptidase,
an enzyme involved in cell wall assembling. On the other hand,
rifapentine aﬀects the RNA polymerase and has been shown to
inhibit curli-dependent bioﬁlm formation without killing the
bacteria at a concentration of a few μg mL−1.49
Bioﬁlm growth is controlled by a variety of physical,
chemical, and biological phenomena, resulting in cell-to-
substrate adhesion and cell-to-cell cohesion events.19 Diﬀerent
from the noncontinuous measurements (data only captured
every 1−2 h), a slight red shift in the wavelength is observed
during the ﬁrst 2 h of the real-time monitoring experiments
(see Figure 3). The LSPR substrate is ﬁrst modiﬁed by an
initial conditioning layer, which promotes the bacteria
anchorage and irreversible adhesion. The observed red shift
is likely due to the increase in the local dielectric constant of
the Au NM structures from the bacterial and protein adhesion
on the Au NM substrates since LSPR signal is sensitive to the
variation in the local dielectric constant of the sample volume,
which extends by ∼30 nm from the top of the Au NM
surface.50 After 2 h, the Au NM LSPR substrate is completely
covered with either bacteria or conditioning biomolecules,
preventing further shifts in the local dielectric constant, and
thus the LSPR signal starts to exhibit blue shifts. This change
of regime is evident in Figure 3b (see the vertical dashed line),
where the sensor response from E. coli in LB without any
antibiotics (red curve) displays a clear peak and a slope change
at about 2 h.
Figure 3a also shows some scattering in the LSPR signal for
E. coli and E. coli treated with rifapentine. They are likely due
to the high turbidity of the sample, caused by large number of
cells in the LSPR-PDMS wells, which makes it diﬃcult to
clearly identify the resonance peak. However, this eﬀect does
not alter the overall wavelength shift in the resonance peak.
The recorded absorbance spectra captured every minute for
all experiments are ﬁtted using a spline function, providing the
resonance wavelength shift data shown in Figure 3a. The
experimental results show that bioﬁlms treated with conven-
tional antibiotics (kanamycin (orange symbols) and ampicillin
(green symbols)) lead to signals similar to the one obtained by
the control experiment (LB in blue symbols); see Figure 3. On
the other hand, rifapentine (gray symbols) at an eﬀective
concentration of 1 μg mL−149 prevents the cell adhesion but
does not eradicate the bacteria, resulting in a smaller
wavelength shift than the one obtained by nontreated E. coli
(red symbols).
Interestingly, the response of the E. coli treated by the mixed
drug system is similar to the one treated with rifapentine
during the ﬁrst 2 h, with the black and the gray curves almost
overlapping (see Figure 3b). However, after 2 h, the resonance
peak from the mixed drug system shifts to a larger wavelength,
reaching similar saturation values as those of the E. coli treated
with ampicillin and kanamycin.
The wavelength shifts from all these cases are ﬁtted by an
exponential model:
λΔ = + −A(1 e ),Bt (2)
where A and B are the amplitude of the exponential and a rate
parameter, respectively.
The comparison of the ﬁtted responses of the tested samples
is shown in Figure 3b. Table 2 shows values of ﬁtted
parameters based on the best ﬁt of the experimental data using
the exponential (eq 2) or/and the logistic (eq 1) type models.
The rate parameters k and t*, the time at which the bioﬁlm
formation rate is maximized, can be correlated with the
dampening eﬀect on the bioﬁlm formation due to an adhesion
inhibiting drug like rifapentine. When rifapentine is added to
the culture medium, surface coating rate (k) is signiﬁcantly
reduced (0.85 ± 0.03 h−1 versus 0.57 ± 0.03 h−1 for E. coli and
E. coli treated with rifapentine, respectively), while the time t*
to achieve half of the wavelength shift (b−a) increases (6.14 ±
0.04 h versus 10.39 ± 0.11 h, respectively). These results can
be very valuable for drug screening studies, since the LSPR
signals can be utilized to identify new molecules, which can be
combined with conventional antibiotics to either prevent the
formation of the microbial superstructure or attack the existing
bioﬁlm.
Figure 4 provides a general summary of the bioﬁlm LSPR
responses under diﬀerent experimental conditions (non-
continuous versus real-time), showing wavelength shifts at
24 h. Note both E. coli - Noncontinuous and E. coli - Real-time
tests shown are performed without any drugs or chemicals. In
the noncontinuous case, the LSPR biochip is mostly kept in an
incubator at 37 °C for the entire experiment, while in the real-
time experiment, the biochip is illuminated with a white light
for 24 h, which results in a slightly smaller wavelength shift
(−11.8 ± 3.4 nm), compared to the noncontinuous test
(−14.8 ± 1.3 nm). Among the real-time experiments, the
control sample (LB), E. coli treated with kanamycin, ampicillin,
and the antibiotic mixture exhibit similar results in the
wavelength shift. This is due to the antimicrobial properties
of the two conventional drugs which kill mostly all the bacteria
Table 2. Parameters Resulting from the Best Fit of the Absorption Maximum Position Data Shown in Figure 3, from the Real-
Time Monitoringa
exponential model logistic-type model
sample A (nm) B (h) a (nm) b (nm) k (h−1) t* (h)
E. coli 2.24 ± 0.02 1.60 ± 0.09 2.5 ± 0.05 −9.64 ± 0.08 0.85 ± 0.03 6.14 ± 0.04
Control (LB) 1.33 ± 0.01 1.49 ± 0.07
E. coli+Kanamycin 0.60 ± 0.01 1.14 ± 0.09
E. coli+Ampicillin 1.03 ± 0.01 1.09 ± 0.05
E. coli+Rifapentine 0.43 ± 0.01 1.20 ± 0.10 0.43 ± 0.01 −4.69 ± 0.06 0.57 ± 0.03 10.40 ± 0.10
E. coli+Mixture 0.77 ± 0.02 0.44 ± 0.03
aThe naked LSPR substrate (control (Air)) shows negligible wavelength shift, hence data not included in this table.
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before they are able to adhere onto the sensor surface and form
the bioﬁlm. On the other hand, the LSPR biochip incubated
with rifapentine-treated E. coli produces a wavelength shift of
−4.8 ± 1.1 nm, which is about 50% of those with nontreated
bacteria cells. These results are consistent with the intended
drug mechanisms of the three antibiotics used: antimicrobial
activity versus bacterial adhesion prevention. Indeed, using a
drug (like refapentine) to attack bioﬁlm formation is not
suﬃcient to ﬁght the bacterial infection. As evidenced by the
response of the LSPR biochip of E. coli treated with a mixture
of antibiotics (E. coli + Mixture series of data in Figure 3 and
Figure 4), a more eﬀective strategy to ﬁght bacterial bioﬁlm is
to combine conventional bacterial killing antibiotics with drugs
that target speciﬁcally to the bioﬁlm structure.
Since the wavelength shift in the adsorption peaks at 24 h is
related to the amount of bacterial cells and EPS absorbed onto
the LSPR substrate, these LSPR signals can be compared with
the standard end-point microbiology assays such as crystal
violet staining assay for the bioﬁlm mass evaluation, see section
below (see protocol details in Experimental Section).
LSPR Sensor Response versus Crystal Violet Staining
and Viability Test. In order to validate the results of our
LSPR-based methodology, two independent standard staining
procedures have been used to compare the mass and cell
viability of bacterial bioﬁlms. Crystal violet (CV) assay is the
most common methodology to evaluate bioﬁlm formation and
is based on the direct measurement of microbial biomass. This
technique is commonly performed by comparing the
absorbance at 570 nm of diﬀerent samples after 24 h bacterial
growth with CV staining, in a 96-well plate. Since this is a
disruptive assay, CV staining does not allow investigations of
dynamic phenomena. After subtracting the contribution of the
culture media (LB), the absorbance intensities at 570 nm for
stained samples of E. coli treated with kanamycin, ampicillin,
and rifapentine are normalized with respect to the intensity
value of nontreated E. coli, which is considered as 100% of the
response of the assay. In Figure 5a, the results provided by CV
staining (blue bars) are compared with the wavelength shifts
(normalized by the 24 h value) captured by our LSPR biochip
(red bars).
Consistent with the results illustrated by our LSPR-based
biosensor, the treatment with kanamycin and ampicillin
provides minor signals since most of the bacteria are killed
by these two antibiotics. On the other hand, the treatment with
rifapentine is less aggressive since it aﬀects only the adhesion
properties of the microbes. This produces an absorbance value
at 570 nm, which is about 50% of the value from the
nontreated E. coli, thus being in excellent agreement with the
measurements provided by our LSPR based biochip.
As previously reported, the oscillation of the electrons
related to the LSPR sensing can lead to local temperature
increase, which can kill bacterial cells.48 As a precaution, we
next evaluate how our LSPR based detection system aﬀects the
cell vitality. For this reason we use the LIVE/DEAD Baclight
Bacterial Viability Kit, which allows us to discriminate between
dead (red dye) and living (green dye) cells by ﬂuorescence
microscopy. This test has been performed directly on the
LSPR Au NM substrate after 24 h of bacterial growth; see
images shown in Figure 5b (I, II, III).
The portion of living cells on a glass slide (Figure 5b panel
I), being used as a control study, yields about 95%. For a non-
illuminated LSPR substrate (Figure 5b panel II), this value is
about 85%. On the other hand, the survival percentage of the
bacteria reduces to 65% on the LSPR biochip used for real-
time measurements (Figure 5b panel III), likely due to the
local stress induced by the continuous light irradiation. This
decrease in vitality for continuously illuminated sample
matches the diﬀerence observed in the LSPR response between
the noncontinuous and real-time LSPR measurements (in
Figure 4). Nevertheless, despite the substrate and stress
inﬂuence on the bacterial cell vitality, the bacterial cells are still
able to multiply and adhere onto the substrate with bioﬁlm
formation. For future research, we plan to include a shutter to
illuminate the LSPR biochip only brieﬂy (few seconds) to
collect the transmitted light. This will reduce the stress applied
to the microbial cells, thus improving their vitality.
■ CONCLUSIONS
We report the application of an LSPR-based sensor for the
direct, real-time, and nondisruptive label-free characterization
of bacterial bioﬁlm in a liquid environment. Our LSPR sensor
platform is able to capture the bioﬁlm assembling kinetics and
illustrate how such process is aﬀected by diﬀerent antibiotics.
The sensing device is based on Au nanoplasmonic structures
realized by a cost-eﬀective nanofabrication process. The
quantiﬁcation of E. coli bioﬁlm formation by our LSPR-based
device shows excellent agreement with the measurements
performed by conventional microbiology techniques (e.g.,
crystal violet assay and viability staining), thus proving the
reliability and the robustness of our approach and paving the
way to its utility as a promising tool for characterizing bacterial
bioﬁlms. Moreover, we demonstrate how eﬃcacy of drugs can
be tested using our LSPR biochips, which lays the foundation
to apply LSPR technology in antibiotic drug discovery. Our
Figure 4. Comparison at 24 h between nontreated E. coli, culture
media LB, and bacteria under diﬀerent antibiotic treatments. Real-
time measurements (E. coli - Real-time) require the continuous
illumination of the sample with a white light, inducing additional
stress on bacteria than noncontinuous measurements (E. coli -
Noncontinuous), which results in a slightly smaller wavelength shift
(−14.8 ± 1.3 nm and −11.8 ± 3.4 nm for E. coli - Noncontinuous and
E. coli - Real-time, respectively). While LB, E. coli treated with
kanamycin, and ampicillin are mostly comparable, the rifapentine-
treated sample produces a signal of −4.8 ± 1.1 nm, which is about
50% of the one due to nontreated cells. Note: The error bars represent
standard error of the mean. Each error bar corresponds to at least 3 sets of
experiments (n ≥ 3).
ACS Sensors Article
DOI: 10.1021/acssensors.8b00287
ACS Sens. 2018, 3, 1499−1509
1506
detection methodology can be easily used on other bacteria
systems and can also be adapted to study mixed-species bioﬁlm
formation. In addition, our real-time setup is extremely ﬂexible
since it can be easily integrated with a temperature control
system and can acquire data for several days without any action
from the operator. One potential future application of our
LSPR system is miniaturized portable version, which can be
valuable for in situ monitoring of bioﬁlm formation in sensitive
areas such as hospitals or food industries where bacterial
contamination is a looming concern.
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Figure 5. (a) Bioﬁlm biomass estimation using CV staining (blue bars) and normalized LSPR sensor responses for various samples (red bars)
where the output of nontreated E. coli represents 100% of the response. The errors bars represent SE. Each error bar corresponds to at least three
sets of experiments. (b) LIVE/DEAD BacLight Bacterial Viability staining to estimate the eﬀect of the nanoplasmonic structures on cells viability.
The experiment is performed using two diﬀerent ﬂuorescent dyes (SYTO 9 and propidium iodide), emitting in the green and red spectral regions,
being speciﬁc for living and dead cells, respectively. Fluorescence images of bacteria growing on glass (I), on LSPR Au NM substrate without light
exposure (II), and on the LSPR biochip at the end of the 24 h real-time measurement (III). (IV) Fractions of living and dead cells in (I), (II), and
(III) images.
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